Sadeer G Al-Kindi1, Petra Buzkova2, Sanyog G Shitole3, Alex P Reiner4, Parveen K Garg5, John S Gottdiener6, Bruce M Psaty7, Jorge R Kizer8. 1. Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio. 2. Department of Biostatistics, University of Washington, Seattle, Washington. 3. Cardiology Section, San Francisco Veterans Affairs Health Care System, and Department of Medicine, University of California San Francisco, San Francisco, California. 4. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington. 5. Division of Cardiology, University of Southern California Keck School of Medicine, Los Angeles, California. 6. Department of Medicine, University of Maryland, Baltimore, Maryland. 7. Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology and Health Services, University of Washington, Seattle, Washington; Kaiser Permanente Washington Research Institute, Seattle, Washington. 8. Cardiology Section, San Francisco Veterans Affairs Health Care System, and Department of Medicine, University of California San Francisco, San Francisco, California; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California. Electronic address: jorge.kizer@ucsf.edu.
Abstract
BACKGROUND: CD14 is a membrane glycoprotein primarily expressed by myeloid cells that plays a key role in inflammation. Soluble CD14 (sCD14) levels carry a poor prognosis in chronic heart failure (HF), but whether elevations in sCD14 precede HF is unknown. We tested the hypothesis that sCD14 is associated with HF incidence and its subtypes independent of major inflammatory biomarkers among older adults. METHODS AND RESULTS: We included participants in the Cardiovascular Health Study without preexisting HF and available baseline sCD14. We evaluated the associations of sCD14, high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, and white blood cell count (WBC) with incident HF and subtypes using Cox regression. Among 5217 participants, 1878 had incident HF over 13.6 years (609 classifiable as HF with preserved ejection fraction [HFpEF] and 419 as HF with reduced ejection fraction [HFrEF]). After adjusting for clinical and laboratory covariates, sCD14 was significantly associated with incident HF (hazard ratio [HR]: 1.56 per doubling, 95% confidence interval [CI]: 1.29-1.89), an association that was numerically stronger than for hsCRP (HR per doubling: 1.10, 95% CI: 1.06-1.15), IL-6 (HR: 1.18, 95% CI: 1.10-1.25), and WBC (HR: 1.24, 95% CI: 1.09-1.42), and that remained significant after adjustment for the other markers of inflammation. This association for sCD14 was observed with HFpEF (HR: 1.50, 95% CI: 1.07-2.10) but not HFrEF (HR: 0.99, 95% CI: 0.67-1.49). CONCLUSIONS: Plasma sCD14 was associated with incident HF independently and numerically more strongly than other major inflammatory markers. This association was only observed with HFpEF in the subset with classifiable HF subtypes. Pending replication, these findings have potentially important therapeutic implications.
BACKGROUND: CD14 is a membrane glycoprotein primarily expressed by myeloid cells that plays a key role in inflammation. Soluble CD14 (sCD14) levels carry a poor prognosis in chronic heart failure (HF), but whether elevations in sCD14 precede HF is unknown. We tested the hypothesis that sCD14 is associated with HF incidence and its subtypes independent of major inflammatory biomarkers among older adults. METHODS AND RESULTS: We included participants in the Cardiovascular Health Study without preexisting HF and available baseline sCD14. We evaluated the associations of sCD14, high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, and white blood cell count (WBC) with incident HF and subtypes using Cox regression. Among 5217 participants, 1878 had incident HF over 13.6 years (609 classifiable as HF with preserved ejection fraction [HFpEF] and 419 as HF with reduced ejection fraction [HFrEF]). After adjusting for clinical and laboratory covariates, sCD14 was significantly associated with incident HF (hazard ratio [HR]: 1.56 per doubling, 95% confidence interval [CI]: 1.29-1.89), an association that was numerically stronger than for hsCRP (HR per doubling: 1.10, 95% CI: 1.06-1.15), IL-6 (HR: 1.18, 95% CI: 1.10-1.25), and WBC (HR: 1.24, 95% CI: 1.09-1.42), and that remained significant after adjustment for the other markers of inflammation. This association for sCD14 was observed with HFpEF (HR: 1.50, 95% CI: 1.07-2.10) but not HFrEF (HR: 0.99, 95% CI: 0.67-1.49). CONCLUSIONS: Plasma sCD14 was associated with incident HF independently and numerically more strongly than other major inflammatory markers. This association was only observed with HFpEF in the subset with classifiable HF subtypes. Pending replication, these findings have potentially important therapeutic implications.
Authors: Ruben Poesen; Ali Ramezani; Kathleen Claes; Patrick Augustijns; Dirk Kuypers; Ian R Barrows; Jagadeesan Muralidharan; Pieter Evenepoel; Björn Meijers; Dominic S Raj Journal: Clin J Am Soc Nephrol Date: 2015-07-07 Impact factor: 8.237
Authors: Alex P Reiner; Ethan M Lange; Nancy S Jenny; Paulo H M Chaves; Jaclyn Ellis; Jin Li; Jeremy Walston; Leslie A Lange; Mary Cushman; Russell P Tracy Journal: Arterioscler Thromb Vasc Biol Date: 2012-11-15 Impact factor: 8.311
Authors: Mary Cushman; Alice M Arnold; Bruce M Psaty; Teri A Manolio; Lewis H Kuller; Gregory L Burke; Joseph F Polak; Russell P Tracy Journal: Circulation Date: 2005-06-27 Impact factor: 29.690
Authors: J Pugin; C C Schürer-Maly; D Leturcq; A Moriarty; R J Ulevitch; P S Tobias Journal: Proc Natl Acad Sci U S A Date: 1993-04-01 Impact factor: 11.205
Authors: Lesley A Stevens; Josef Coresh; Christopher H Schmid; Harold I Feldman; Marc Froissart; John Kusek; Jerome Rossert; Frederick Van Lente; Robert D Bruce; Yaping Lucy Zhang; Tom Greene; Andrew S Levey Journal: Am J Kidney Dis Date: 2008-03 Impact factor: 8.860
Authors: Patrice D Cani; Jacques Amar; Miguel Angel Iglesias; Marjorie Poggi; Claude Knauf; Delphine Bastelica; Audrey M Neyrinck; Francesca Fava; Kieran M Tuohy; Chantal Chabo; Aurélie Waget; Evelyne Delmée; Béatrice Cousin; Thierry Sulpice; Bernard Chamontin; Jean Ferrières; Jean-François Tanti; Glenn R Gibson; Louis Casteilla; Nathalie M Delzenne; Marie Christine Alessi; Rémy Burcelin Journal: Diabetes Date: 2007-04-24 Impact factor: 9.461
Authors: Jacques Amar; Jean B Ruidavets; Claire Bal Dit Sollier; Vanina Bongard; Henri Boccalon; Bernard Chamontin; Ludovic Drouet; Jean Ferrières Journal: J Hypertens Date: 2003-10 Impact factor: 4.844
Authors: B M Psaty; L H Kuller; D Bild; G L Burke; S J Kittner; M Mittelmark; T R Price; P M Rautaharju; J Robbins Journal: Ann Epidemiol Date: 1995-07 Impact factor: 3.797
Authors: Monali Shah; Carlos J Rodriguez; Traci M Bartz; Mary F Lyles; Jorge R Kizer; Gerard P Aurigemma; Julius M Gardin; John S Gottdiener Journal: Am J Cardiol Date: 2021-06-24 Impact factor: 3.133